Skip to main content
Assets
GSK logo
GSK.LSE
GSK
Health Care · Pharmaceuticals

Pharmaceutical and healthcare company developing medicines, vaccines, and consumer healthcare products across global markets.

HQ: United KingdomListed: United Kingdom

Historical AI Forecasts

Audit every published iPulse AI forecast batch and immutable historical research document for GSK.

Historical AI Forecasts

GSK plc (GSK.LSE) AI FORECASTS & ADVISOR ANALYSIS

Read and compare the 11 individual AI Advisor deep-dive reports, including their forecast paths, ratings, price targets, and reasoning.

Updated on 3 May 2026Deep analysis 3 May 2026

PublisherRusslan Ramdowar
25 min readAudit All Past Forecasts
Superintelligence AI advisor icon

Superintelligence AI

The Anthropologist FrameworkAI Researcher

Model rating

Buy

5-Year Return Est.

+65.2%

Includes 0.04% annual net dividend contribution

1. Investment Thesis — Base Case

What is the '' path when we strip away the noise? The base case projects steady compounding as GSK completes its transformation from a sluggish legacy incumbent into a geopolitically insulated negentropy engine. Despite the near-term friction of declining general medicines and RSV saturation, the specialty medicine and oncology segments will continue to compound. The underlying math supports a strong upward trajectory as their structural advantages outpace legacy decay. As the global macroeconomic environment fragments under energy blockades and trade shocks, GSK’s deep biological demand layer will command a from risk-averse capital.

  • The company successfully leverages its United States Section 232 tariff exemption to capture from penalized foreign competitors.
  • The $2.2 billion Zantac settlement holds firm, removing a generational cap on inflows.
  • Research and development transitions from costly probabilistic trials to deterministic virtual cell models, radically expanding .
  • Accelerated 28% oncology growth and Shingrix durability mathematically outpace the declining RSV and general medicine revenues.
  • High-margin biologic effortlessly withstands global energy and .

Ultimately, the structural United States trade protection and AI-optimized pipeline will force the market to reprice the asset upward, overcoming near-term earnings friction and fulfilling the 2031 outlook.

Historical prices and published forecast

Historical prices and published forecastObserved prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in GBX.1.08K1.64K2.2K2.76K3.32KApr 2021Oct 2023Apr 2026Oct 2028May 2031Forecast starts
  • Observed price
  • Published advisor forecast
Observed prices and the selected advisor's published projection share a split-adjusted price basis. Prices after the forecast start are later observations, not information known at publication. Forecasts are uncertain. Values in GBX.
View chart values
Historical prices and published forecast — published chart values
SeriesDateValue (GBX)
Observed price2021-04-291,344
Observed price2021-05-151,380
Observed price2021-06-011,354
Observed price2021-06-131,421
Observed price2021-06-221,410
Observed price2021-07-041,446
Observed price2021-07-121,458
Observed price2021-07-251,416
Observed price2021-08-061,455
Observed price2021-08-191,535
Observed price2021-08-311,491
Observed price2021-09-171,414
Observed price2021-10-031,397
Observed price2021-10-161,418
Observed price2021-10-201,427
Observed price2021-11-091,586
Observed price2021-11-141,595
Observed price2021-11-301,542
Observed price2021-12-081,610
Observed price2021-12-171,632
Observed price2022-01-061,612
Observed price2022-01-191,680
Observed price2022-01-271,694
Observed price2022-02-171,594
Observed price2022-03-051,515
Observed price2022-03-141,579
Observed price2022-03-181,626
Observed price2022-04-071,795
Observed price2022-04-241,757
Observed price2022-04-281,824
Observed price2022-05-111,738
Observed price2022-05-231,789
Observed price2022-05-311,737
Observed price2022-06-171,702
Observed price2022-07-031,800
Observed price2022-07-121,722
Observed price2022-07-201,757
Observed price2022-08-101,476
Observed price2022-08-141,416
Observed price2022-09-031,349
Observed price2022-09-121,374
Observed price2022-09-201,307
Observed price2022-10-021,326
Observed price2022-10-231,379
Observed price2022-10-311,439
Observed price2022-11-171,370
Observed price2022-11-211,380
Observed price2022-12-121,449
Observed price2022-12-161,433
Observed price2022-12-241,451
Observed price2023-01-141,434
Observed price2023-01-221,405
Observed price2023-02-081,480
Observed price2023-02-241,446
Observed price2023-03-051,434
Observed price2023-03-131,378
Observed price2023-03-251,408
Observed price2023-04-071,523
Observed price2023-04-191,477
Observed price2023-04-271,446
Observed price2023-05-141,460
Observed price2023-05-311,370
Observed price2023-06-161,371
Observed price2023-06-241,417
Observed price2023-07-111,318
Observed price2023-07-231,395
Observed price2023-07-271,399
Observed price2023-08-051,356
Observed price2023-08-211,357
Observed price2023-09-111,458
Observed price2023-09-151,486
Observed price2023-09-231,532
Observed price2023-10-101,514
Observed price2023-10-311,430
Observed price2023-11-161,387
Observed price2023-11-251,417
Observed price2023-11-291,421
Observed price2023-12-151,452
Observed price2023-12-241,450
Observed price2024-01-091,576
Observed price2024-01-261,525
Observed price2024-02-071,668
Observed price2024-02-111,629
Observed price2024-02-191,678
Observed price2024-03-071,708
Observed price2024-03-191,647
Observed price2024-04-011,664
Observed price2024-04-171,599
Observed price2024-04-261,648
Observed price2024-05-121,803
Observed price2024-05-211,786
Observed price2024-06-101,618
Observed price2024-06-141,611
Observed price2024-07-051,510
Observed price2024-07-091,512
Observed price2024-07-301,545
Observed price2024-08-071,540
Observed price2024-08-241,613
Observed price2024-09-011,654
Observed price2024-09-181,592
Observed price2024-09-221,546
Observed price2024-10-041,487
Observed price2024-10-171,482
Observed price2024-11-061,385
Observed price2024-11-101,370
Observed price2024-11-191,310
Observed price2024-12-091,369
Observed price2024-12-221,327
Observed price2025-01-031,360
Observed price2025-01-161,334
Observed price2025-01-241,370
Observed price2025-02-051,482
Observed price2025-02-221,440
Observed price2025-03-101,516
Observed price2025-03-151,510
Observed price2025-04-041,393
Observed price2025-04-081,266
Observed price2025-04-291,435
Observed price2025-05-121,359
Observed price2025-05-241,440
Observed price2025-06-101,523
Observed price2025-06-181,446
Observed price2025-06-301,391
Observed price2025-07-131,414
Observed price2025-07-171,402
Observed price2025-07-211,350
Observed price2025-08-111,406
Observed price2025-08-231,474
Observed price2025-09-171,474
Observed price2025-09-211,488
Observed price2025-09-291,627
Observed price2025-10-201,644
Observed price2025-10-241,646
Observed price2025-11-141,807
Observed price2025-11-221,778
Observed price2025-12-051,828
Observed price2025-12-251,810
Observed price2026-01-021,862
Observed price2026-01-071,894
Observed price2026-01-191,814
Observed price2026-01-311,957
Observed price2026-02-172,254
Observed price2026-02-252,208
Observed price2026-03-181,969
Observed price2026-03-221,939
Observed price2026-04-122,155
Observed price2026-04-162,135
Observed price2026-05-071,860
Observed price2026-05-231,915
Observed price2026-06-011,863
Observed price2026-06-051,878
Observed price2026-06-251,961
Observed price2026-07-042,003
Observed price2026-07-201,890
Observed price2026-07-282,008
Observed price2026-08-141,824
Observed price2026-08-181,907
Observed price2026-09-081,799
Observed price2026-09-151,854
Observed price2026-09-171,900
Observed price2026-09-181,878
Published advisor forecast2026-05-011,901
Published advisor forecast2026-08-011,996
Published advisor forecast2026-11-012,036
Published advisor forecast2027-02-012,158
Published advisor forecast2027-05-012,180
Published advisor forecast2027-08-012,245
Published advisor forecast2027-11-012,290
Published advisor forecast2028-02-012,382
Published advisor forecast2028-05-012,334
Published advisor forecast2028-08-012,404
Published advisor forecast2028-11-012,452
Published advisor forecast2029-02-012,550
Published advisor forecast2029-05-012,576
Published advisor forecast2029-08-012,653
Published advisor forecast2029-11-012,706
Published advisor forecast2030-02-012,814
Published advisor forecast2030-05-012,786
Published advisor forecast2030-08-012,842
Published advisor forecast2030-11-012,927
Published advisor forecast2031-02-013,073
Published advisor forecast2031-05-013,135

2. Scenarios & Signals

Bull case

What happens if the best-case variables align? If the Base Case materializes and the Bepirovirsen functional cure achieves rapid global dominance, GSK will aggressively re-rate as a top-tier growth asset. Furthermore, the United States tariff protection could act as a massive force multiplier, allowing GSK to effectively monopolize key specialty corridors as foreign peers retreat, pushing the valuation well beyond standard models.

  • Bepirovirsen captures the massive chronic Hepatitis B market, adding >£3 billion in peak sales.
  • The United States tariff exemption creates an impenetrable pricing moat, dramatically inflating .
  • AI-native discovery perfectly compresses Phase II trial attrition, doubling research .
  • The stock captures overwhelming defensive inflows amid prolonged geopolitical and economic stagnation.

Bear case

What happens if the entropy accelerates? If the aging General Medicines portfolio deteriorates faster than Specialty growth can offset, and Medicare lien delays unravel the Zantac settlement framework, the stock will languish. A failure in the antimicrobial resistance pipeline could leave the company exposed to a shrinking late-stage portfolio, fundamentally turning it into a thermodynamic .

  • Zantac settlement delays trigger renewed litigation, permanently spooking risk-averse .
  • Arexvy sales collapse entirely under superior competitor efficacy and demographic saturation.
  • The pricing concessions severely restrict United States revenue, while the tariff moat proves porous to rivals.
  • The research pipeline stalls, proving the partnerships were merely performative tech-washing rather than real science.

Current crowd narrative

What does the noisy market currently believe? The crowd sees a sluggish legacy pharmaceutical company struggling with an aging product line and inconsistent execution. Following the significant Q1 2026 earnings miss and an 18% drop in RSV vaccine sales, financial media paints GSK as a . The consensus assumes that their AI partnerships are merely performative 'tech-washing' and that their general medicines will continue to drag down overall growth. They anchor heavily on recent execution errors, treating the company as a rather than an innovation engine.

Alpha-gap assessment

What is the crowd systematically ignoring? They are missing the profound geopolitical arbitrage GSK just engineered. By securing a Section 232 tariff exemption via the agreement, GSK essentially walled off its US from foreign competition facing a 100% import tax. The market prices in the near-term pricing concessions but entirely ignores the long-term volume and margin protection this provides. Furthermore, the crowd misunderstands the thermodynamic shift in their research and development. Licensing like Noetik transitions their pipeline from probabilistic guesswork to deterministic simulation, structurally improving .

Convergence catalyst

What will force the market to wake up? The will close as Q3 and Q4 2026 earnings reveal the catastrophic US margin collapse of non-exempt European competitors, contrasting sharply with GSK's insulated US cash flows. Additionally, successful late-stage clinical readouts for Bepirovirsen in early 2027 will validate the new AI-driven model, forcing a fundamental .

Complete advisor preview locked

Unlock this report and every AI Advisor

Sign in to check your access, or upgrade to the Base plan to read this report and open every advisor.

Sign in to check accessView Base planReturn to latest AI Consensus